Gastric inhibitory polypeptide in newly diagnosed ketotic type I (insulin-dependent) diabetics

Acta Med Scand. 1988;223(5):437-41. doi: 10.1111/j.0954-6820.1988.tb15895.x.

Abstract

Plasma concentrations of 5,000 daltons (5 kDa) immunoreactive gastric inhibitory polypeptide (IR-GIP) were measured before and up to 16 hours after the start of low-dose insulin treatment in newly diagnosed ketotic type I (insulin-dependent) diabetics. Nine patients were non-fasting. Before insulin treatment mean IR-GIP was 31 +/- 6 pmol/l (range 9-65 pmol/l). Four patients had IR-GIP concentrations in the normal fasting range (10-25 pmol/l), and nine patients had concentrations below 35 pmol/l. The remaining patients had IR-GIP concentrations in the normal postprandial range. A meal eaten after the start of insulin treatment caused an increase in IR-GIP in all patients. All patients had beta-cell function as estimated by plasma C-peptide. Individual changes in C-peptide were significantly correlated to changes in blood glucose both after the meal (r = 0.80, p less than 0.01) and during insulin treatment (r = 0.85 +/- 0.04). No correlation could be found between IR-GIP and blood glucose, C-peptide or insulin concentrations. Newly diagnosed ketotic type I diabetics have IR-GIP concentrations within the normal postprandial level. Hypoinsulinaemia, hyperglycaemia, and hyperketonaemia do not by themselves increase 5 kDa IR-GIP markedly above normal fasting levels.

MeSH terms

  • Adolescent
  • Adult
  • Blood Glucose / analysis
  • C-Peptide / blood
  • Diabetes Mellitus, Type 1 / blood*
  • Diabetes Mellitus, Type 1 / drug therapy
  • Female
  • Gastric Inhibitory Polypeptide / blood*
  • Humans
  • Insulin / blood
  • Insulin / therapeutic use
  • Male

Substances

  • Blood Glucose
  • C-Peptide
  • Insulin
  • Gastric Inhibitory Polypeptide